Developments First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of... October 2, 2025